Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles

Molecular Pharmacology

Volumn 76, Issue 5, 2009, Pages 1053-1061

  Brueggemann, Lioubov I ^a   Mackie, Alexander R ^a   Mani, Bharath K ^a   Cribbs, Leanne L ^a   Byron, Kenneth L ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIMETHYLCELECOXIB; CALCIUM; CALCIUM CHANNEL L TYPE; CELECOXIB; DICLOFENAC; FURA 2; POTASSIUM CHANNEL KCNQ; ROFECOXIB; UNCLASSIFIED DRUG; VASOPRESSIN;

ANIMAL CELL; AORTA; ARTERY CONSTRICTION; ARTICLE; CALCIUM CURRENT; CALCIUM TRANSPORT; CARDIOVASCULAR RISK; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FLUORESCENCE; MESENTERIC ARTERY; MYOGRAPHY; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; CALCIUM SIGNALING; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CELLS, CULTURED; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; ION CHANNELS; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS; VASCULAR RESISTANCE;

EID: 70350452558     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.057844     Document Type: Article

References (37)

1. Aw TJ, Haas SJ, Liew D, and Krum H (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165:490-496. (Pubitemid 40344379)
2. Brueggemann LI, Martin BL, Barakat J, Byron KL, and Cribbs LL (2005) Low voltage-activated calcium channels in vascular smooth muscle: T-type channels and AVP-stimulated calcium spiking. Am J Physiol Heart Circ Physiol 288:H923-H935. (Pubitemid 40139681)
3. Brueggemann LI, Moran CJ, Barakat JA, Yeh JZ, Cribbs LL, and Byron KL (2007) Vasopressin stimulates action potential firing by protein kinase C-dependent inhibition of KCNQ5 in A7r5 rat aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 292:H1352-H1363.
4. Byron KL (1996) Vasopressin stimulates Ca2+ spiking activity in A7r5 vascular smooth muscle cells via activation of phospholipase A2. Circ Res 78:813-820. (Pubitemid 126424516)
5. 2+ spiking in a vascular smooth muscle cell line is independent of the release of intracellular Ca2+ stores. J Biol Chem 268:6945-6952.
6. Cho J, Cooke CE, and Proveaux W (2003) A retrospective review of the effect of COX-2 inhibitors on blood pressure change. Am J Ther 10:311-317.
7. Delmas P and Brown DA (2005) Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 6:850-862. (Pubitemid 41568727)
8. Frolov RV, Berim IG, and Singh S (2008a) Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it. J Biol Chem 283:1518-1524.
9. Frolov RV, Slaughter MM, and Singh S (2008b) Effects of celecoxib on ionic currents and spontaneous firing in rat retinal neurons. Neuroscience 154:1525-1532.
10. Henderson KK and Byron KL (2007) Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways. J Appl Physiol 102:1402-1409. (Pubitemid 46571034)
11. Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, et al. (2003) Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 108:2308-2311. (Pubitemid 37413534)
12. Hinz B, Dormann H, and Brune K (2006) More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 54:282-291. (Pubitemid 43122213)
13. Jentsch TJ (2000) Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 1:21-30.
14. Klein T, Eltze M, Grebe T, Hatzelmann A, and Kömhoff M (2007) Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovasc Res 75:390-397. (Pubitemid 46961916)
15. Lange W, Geissendörfer J, Schenzer A, Grötzinger J, Seebohm G, Friedrich T, and Schwake M (2009) Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol 75:272-280.
16. Lundblad MS, Ohlsson S, Johansson P, Lafolie P, and Eliasson E (2006) Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3. Clin Pharmacol Ther 79:287-288. (Pubitemid 43297021)
17. Mackie AR, Brueggemann LI, Henderson KK, Shiels AJ, Cribbs LL, Scrogin KE, and Byron KL (2008) Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 325:475-483.
18. Mackie AR and Byron KL (2008) Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention. Mol Pharmacol 74:1171-1179.
19. Mani BK, Brueggemann LI, Cribbs LL, and Byron KL (2009) Opposite regulation of KCNQ5 and TRPC6 channels contributes to vasopressin-stimulated calcium spiking responses in A7r5 vascular smooth muscle cells. Cell Calcium 45:400-411.
20. Mardini IA and FitzGerald GA (2001) Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs. Mol Interv 1:30-38.
21. Marnett LJ (2009) The COXIB experience: a look in the rear-view mirror. Annu Rev Pharmacol Toxicol 49:265-290.
22. McGettigan P and Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296:1633-1644. (Pubitemid 44511610)
23. Patrono C, Patrignani P, and García Rodríguez LA (2001) Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108:7-13. (Pubitemid 32634915)
24. Peretz A, Degani-Katzav N, Talmon M, Danieli E, Gopin A, Malka E, Nachman R, Raz A, Shabat D, and Attali B (2007) A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives. PLoS ONE 2:e1332.
25. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, and Attali B (2005) Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol 67:1053-1066. (Pubitemid 40410406)
26. Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, Uddin J, Petasis NA, Mircheff AK, Farley RA, et al. (2007) Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther 6:1262-1275. (Pubitemid 46711989)
27. Sauter ER, Qin W, Hewett JE, Ruhlen RL, Flynn JT, Rottinghaus G, and Chen YC (2008) Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women. BMC Cancer 8:49. (Pubitemid 351338724)
28. + channel sensitivity to the anticonvulsant retigabine. J Neurosci 25:5051-5060.
29. Schönthal AH, Chen TC, Hofman FM, Louie SG, and Petasis NA (2008) Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Invest Drugs 17:197-208.
30. Shi S and Klotz U (2008) Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 64:233-252.
31. Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, and Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators (2005) The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 165:161-168.
32. Standen NB and Quayle JM (1998) K+ channel modulation in arterial smooth muscle. Acta Physiol Scand 164:549-557.
33. White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, and Verburg KM (2007) Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 99:91-98. (Pubitemid 44969347)
34. Wickenden AD, Yu W, Zou A, Jegla T, and Wagoner PK (2000) Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 58:591-600. (Pubitemid 30683000)
35. Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney JF Jr, Morrow JD, et al. (2003) Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42:310-315. (Pubitemid 37093478)
36. Wladyka CL and Kunze DL (2006) KCNQ/M-currents contribute to the resting membrane potential in rat visceral sensory neurons. J Physiol 575:175-189.
37. Zhang Y, Tao J, Huang H, Ding G, Cheng Y, and Sun W (2007) Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells. Pharmacol Res 56:267-274. (Pubitemid 47321211)